OncoMatch/Clinical Trials/NCT06714591
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
Is NCT06714591 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies BL-M11D1 for relapsed/refractory acute myeloid leukemia.
Treatment: BL-M11D1 — The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: CD33 expression (testing required; no eligibility threshold specified)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard of care therapy
Cannot have received: topoisomerase inhibitor-based antibody-drug conjugate
Lab requirements
Kidney function
creatinine clearance ≥50 ml/min (cockcroft-gault, ckd-epi, or mdrd equations)
Liver function
total bilirubin (tbil) ≤1.5×uln (≤3×uln for subjects with gilbert's syndrome), ast and alt ≤2.5×uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- UCLA Ronald Reagan Medical Center · Los Angeles, California
- University of Colorado Anschutz Medical Campus · Aurora, Colorado
- Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven · New Haven, Connecticut
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06714591 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior topoisomerase inhibitor-based antibody-drug conjugate disqualifies patients from enrollment.
Does this trial require CD33?
Yes, CD33 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages